-
Teva Says Its Generic EpiPen Will Be 'Significantly Delayed'
Tuesday, March 1, 2016 - 2:53pm | 229Read More...Teva Pharmaceutical Industries Ltd (ADR) (NYSE: TEVA) announced in a regulatory filing on Monday that it has received notice from the U.S. Food and Drug Administration (FDA) related to its epinephrine. Teva said that the FDA identified "certain major deficiencies" and now expects its epinephrine...
-
Going From Philidor To Walgreens Gives Valeant Credibility, But There Are Still Questions
Wednesday, December 16, 2015 - 10:18am | 441Read More...Valeant Pharmaceuticals Intl Inc (NYSE: VRX) stock surged to 12.50 percent to $109.80 in Tuesday's afternoon trading session, following its new 20-year deal announcement to cut prices for Walgreens Boots Alliance Inc (NASDAQ: WBA). The drug deal comes six weeks after the company had cut ties with...
-
Should Biotech Investors Take Hillary Clinton's Drug Pricing Plan Seriously?
Wednesday, September 23, 2015 - 7:56am | 584Read More...Democratic presidential frontrunner Hillary Clinton has sent biotech stocks plummeting this week after announcing the creation of a new plan to fight drug price gouging. Evercore ISI believes that there is a very slim chance the plan will ever become law. Political analyst Terry Haines...
-
Mylan-Perrigo Buyout Offer: What's Next?
Monday, September 14, 2015 - 11:51am | 276Read More...Mylan NV (NASDAQ: MYL) shares have slipped 13 percent this year, while Perrigo Company plc Ordinary Shares (NYSE: PRGO) shares have gained 8 percent. In an expected move, Mylan offered a combined cash and stock offer of $186.895 for Perrigo, which included $75 in cash and 2.3 Mylan shares...
-
Is Mylan's FDA Warning Letter Worth Worrying About?
Tuesday, August 18, 2015 - 2:33pm | 331Read More...Mylan NV (NASDAQ: MYL) commented publicly for the first time to a FDA warning letter which it received on August 6, relating to its Agila Specialty Formulation Facility (SFF), Sterile Product Division (SPD), and Onco Therapies Limited (OTL) sites in India. In a press release, Mylan's CEO...
-
Allergan Earnings Are On Deck: Here's Why They Should Meet Expectations
Wednesday, August 5, 2015 - 11:29am | 307Read More...Allergan PLC (NYSE: AGN) is scheduled to announce its second quarter financial results before the market opens on Thursday. Ahead of the report, Evercore ISI analysts Umer Raffat and Dan Chung went through IMS data, pricing trends, transcripts, and other documents “to put everything in one...
-
Why Is The Medicines Company Stock Falling? This Analyst May Have An Answer
Wednesday, July 29, 2015 - 2:53pm | 337Read More...Shares of The Medicines Company (NASDAQ: MDCO) tumbled more than 5 percent Wednesday after the company reported its second-quarter results before the market opened. Shares opened the day for trading at $32.77 and quickly moved lower to $31.08 before slightly rebounding. Umer Raffat, Evercore ISI's...
-
Is Teva A Better Target For Mylan Than Perrigo? 2 Analysts Share Their Thoughts
Wednesday, April 8, 2015 - 4:00pm | 447Read More...Mylan NV (NASDAQ: MYL) said Wednesday it has offered to acquire rival Perrigo Company (NYSE: PRGO) for $28.9 billion or $205 a share Umer Raffat of Evercore ISI had a chance to chat with Mylan’s management recently. The Mylan-Perrigo accretion “looks something like 10-15%...
